Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck(German Center for Lung Research), Julie R. Brahmer(Johns Hopkins University), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Nir Peled(Shaare Zedek Medical Center), Maya Gottfried(Meir Medical Center), Suman Rao(MedStar Franklin Square Medical Center), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Andrew Robinson(University of California, Riverside), Katsuyuki Hotta(Okayama University Hospital), Tibor Csőszi, M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ali Tafreshi, Jonathan W. Riess(University of California Davis Medical Center), Sinéad Cuffe(Cancer Trials Ireland), Andrea Fülöp(Országos Korányi Tbc és Pulmonológiai Intézet), Bin Zhao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary O’Brien(Royal Marsden NHS Foundation Trust), Erin Jensen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rina Hui(The University of Sydney)
Cited by 1,147
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k